{"product_id":"immunotherapy-in-alzheimers-disease-hardback-9781394336210","title":"Immunotherapy in Alzheimer's Disease (Hardback) 9781394336210","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eImmunotherapy in Alzheimer's Disease\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003ePrashant Tiwari (Edited by), P Tiwari (Author), Sunil Kumar Kadiri (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9781394336210, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 13 July 2026\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e720 pages\u003cbr\u003e25 x 15 x 1.5 cm, 0.666 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003eDiscover a groundbreaking path forward in the fight against dementia with this vital resource, which bridges the gap between costly drug discovery and the transformative potential of harnessing the immune system to finally target the underlying mechanisms of Alzheimer’s disease.\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003eAlzheimer’s disease, which is characterized by a progressive loss of memory and cognitive function, is the most prevalent type of dementia in adults. Despite being widespread, there is currently no permanent treatment for this condition. Current drugs provide only symptomatic relief with serious adverse consequences. The process of discovering new medications in this field is costly and time-consuming, so despite effort on the part of the scientific and pharmaceutical communities, few Alzheimer’s medications have been created. \u003c\/p\u003e\n\u003cp\u003eThis book offers a comprehensive exploration of how the immune system can be harnessed to combat one of the most challenging neurodegenerative disorders of our time. It examines the scientific foundations of immunotherapy, including antibody-based strategies, vaccine development, and modulation of innate and adaptive immune responses. It highlights the interplay between amyloid and tau pathology, neuroinflammation, and microglial activation, providing readers with a clear understanding of the mechanisms driving therapeutic innovation. \u003c\/p\u003e\n\u003cp\u003eBeyond the laboratory, this volume bridges preclinical research with clinical applications, addressing safety, efficacy, and regulatory considerations. Case studies, emerging technologies, and future directions are presented to illustrate both the promise and the challenges of immunotherapy in Alzheimer’s care. Designed for neuroscientists, pharmacologists, clinicians, and biotechnology professionals, the book serves as a vital resource for those seeking evidence-based insights into cutting-edge therapeutic approaches that may transform the landscape of Alzheimer’s treatment.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003ePreface xxvii\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Immunotherapy: Unveiling Myths, Shaping Reality, Charting Ideas, and Mapping the Future 1\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eK. Trideva Sastri, Dinesh Murugan M., Meghana G.S. and Balamuralidhara V.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Introduction 2\u003cbr\u003e1.2 Understanding Immunotherapy in Alzheimer's Disease 5\u003cbr\u003e1.3 Unveiling the Myths Surrounding Immunotherapy 8\u003cbr\u003e1.4 Shaping the Reality of Immunotherapy 11\u003cbr\u003e1.5 Charting Ideas: Emerging Trends in Immunotherapy 13\u003cbr\u003e1.6 Mapping the Future of Alzheimer's Care with Immunotherapy 24\u003cbr\u003e1.7 Overcoming Barriers in Translating Research to Clinical Practice in Immunotherapy Treatment of Alzheimer's Disease 26\u003cbr\u003e1.8 Conclusion 28\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Amyloid-β Immunotherapy: Bridging Gaps in Alzheimer's Strategies 49\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eP. K. Sahu, S. K. Prusty, M. Khandai and D. S. Panda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Introduction 50\u003cbr\u003e2.2 AD Pathogenesis 51\u003cbr\u003e2.3 Advances in AD Treatment 52\u003cbr\u003e2.4 Advantages and Challenges 67\u003cbr\u003e2.5 Bridging Gaps in Alzheimer's Strategies 68\u003cbr\u003e2.6 Conclusion 70\u003cbr\u003e2.7 Future Directions 70\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Advancing Strain-Specific Immunotherapy for Alzheimer's Disease and Tauopathies: Opportunities and Challenges 79\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eSindhu Priya E. S., Sandhya Vasanth, Tahreen Taj, Mohammed Ameen M. P., Seleshya S. Danam and M. Vijay Kumar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Introduction 80\u003cbr\u003e3.2 Background on Alzheimer's Disease and Tauopathies 82\u003cbr\u003e3.3 Current Immunotherapy Approaches for Alzheimer's Disease 86\u003cbr\u003e3.4 Rationale for Strain-Specific Immunotherapy 90\u003cbr\u003e3.5 Opportunities in Strain-Specific Immunotherapy 92\u003cbr\u003e3.6 Innovative Techniques in Strain-Specific Targeting 93\u003cbr\u003e3.7 Preclinical and Clinical Studies: Current Status and Findings 94\u003cbr\u003e3.8 Future Directions and Emerging Trends 104\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Synergistic Approaches: Natural Products, Small Molecules, and Immunotherapy in Brain Disorder Management 119\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePrashant Tiwari, Sunil Kumar Kadiri, Neha Minocha and Astha Singh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Introduction 120\u003cbr\u003e4.2 Natural Products in Brain Disorder Management 123\u003cbr\u003e4.3 Small Molecules in Brain Disorder Management 132\u003cbr\u003e4.4 Immunotherapy in Brain Disorder Management 137\u003cbr\u003e4.5 Synergistic Approaches 139\u003cbr\u003e4.6 Emerging Trends and Innovations in Synergistic Approaches for Brain Disorder Management 145\u003cbr\u003e4.7 Challenges 146\u003cbr\u003e4.8 Future Directions 148\u003cbr\u003e4.9 Conclusion 151\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Deciphering the Role of Cytokines in Neuroinflammation: Implications for Therapeutic Targeting 161\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eKushagra Nagori, Rashnita Sharma, Anshita Shukla, Reena Deshmukh, Rashi Banchhor, Kartik T. Nakhate, Madhulika Pradhan, Krishna Yadav, Mukesh Kumar Sharma and Aakash Gupta\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Introduction 163\u003cbr\u003e5.2 CY Families and Their Role in Neuroinflammation 164\u003cbr\u003e5.3 Cellular Sources of CY in the CNS 166\u003cbr\u003e5.4 Mechanisms of CY Signaling in the CNS 170\u003cbr\u003e5.5 Anti-Inflammatory CY: Regulation and Therapeutic Potential 172\u003cbr\u003e5.6 CY Dysregulation in Specific Neurodegenerative Disorders 173\u003cbr\u003e5.7 Therapeutic Targeting of CY 175\u003cbr\u003e5.8 Conclusion 176\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Therapeutic Potential of TREM-1 Modulation in Alzheimer's Disease 185\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePragati A. Dongare, Deepak Khobragade, Surendra Agrawal and Mrunali Potbhare\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Introduction 186\u003cbr\u003e6.2 TREM-1: Structure and Function 190\u003cbr\u003e6.3 TREM-1 in Neuroinflammation and AD 192\u003cbr\u003e6.4 Potential Mechanisms of TREM-1 Modulation in AD Therapy 194\u003cbr\u003e6.5 Therapeutic Strategies Targeting TREM-1 in AD 196\u003cbr\u003e6.6 Preclinical and Clinical Studies on TREM-1 in AD 198\u003cbr\u003e6.7 Challenges and Future Perspectives 199\u003cbr\u003e6.8 Conclusions 201\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Personalized Immunotherapy in Brain Disorders: Precision Medicine Insights 209\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eBhaskar Pal, Kushal Roychoudhuri and Moitreyee Chattopadhyay\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Introduction 210\u003cbr\u003e7.2 Overview of Precision Medicine 211\u003cbr\u003e7.3 Immunotherapy Technologies 213\u003cbr\u003e7.4 Personalized Immunotherapy Targeting Cancer-Specific Neoantigen 221\u003cbr\u003e7.5 Role of Emerging Biomarkers for Personalized Immunotherapies 222\u003cbr\u003e7.6 Challenges and Limitations of Recent Biomarkers to Identify Response to Immune Therapies 223\u003cbr\u003e7.7 Use for Brain Diseases 224\u003cbr\u003e7.8 Technology Innovation 228\u003cbr\u003e7.9 Clinical Trials 229\u003cbr\u003e7.10 Challenges and Limitations 231\u003cbr\u003e7.11 Future Direction 232\u003cbr\u003e7.12 Conclusion 233\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Hematological Considerations in Immunotherapy for Alzheimer's Disease 247\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eRitu Raj Kumar, Rohit Pandey, Sonakshi Antal, Shobha Rani and Md. Sarfraj Alam\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Introduction 248\u003cbr\u003e8.2 Patient-Centered Perspectives in Immunotherapy for Alzheimer's Disease 256\u003cbr\u003e8.3 Future Directions in Immunotherapy for Alzheimer's Disease 261\u003cbr\u003e8.4 Conclusion 263\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Innovative Strategies for Genetic Predispositions in Alzheimer's: Immunotherapy and Gene Therapy Integration 273\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eShukla Rajendra Kumar, Shah Nishi, Bohra Bhavna, Saxena Bhagawati and Gupta Richa\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Introduction to Alzheimer's Disease 274\u003cbr\u003e9.2 Global Statics of Alzheimer's Disease 275\u003cbr\u003e9.3 Pathophysiology of Alzheimer's: Amyloid Plaques, Neurofibrillary Tangles, and Neuroinflammation 275\u003cbr\u003e9.4 Current Diagnostic Challenges and the Need for Innovative Approaches 280\u003cbr\u003e9.5 Gene Therapy: Harnessing Genetic Engineering for Alzheimer's 280\u003cbr\u003e9.6 Immunotherapy: A Promising Frontier in Alzheimer's Treatment 284\u003cbr\u003e9.7 Integrating Immunotherapy and Gene Therapy: A Synergistic Approach 290\u003cbr\u003e9.8 Preclinical and Clinical Trials: Progress and Challenges 292\u003cbr\u003e9.9 Conclusion: The Road Ahead for Alzheimer's Treatment 294\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Facilitating Synaptic Repair: Immune System Involvement 305\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eGaurav Mude, Mohammad Tauqeer Sheikh, Shantilal Singune, Sanjay Nagdev and Junaid Tantray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Introduction to Synaptic Repair 306\u003cbr\u003e10.2 The Immune System and the Central Nervous System (CNS) 307\u003cbr\u003e10.3 Microglia: Sentinels and Sculptors of Synaptic Networks 310\u003cbr\u003e10.4 Astrocytes and Synaptic Support 313\u003cbr\u003e10.5 Peripheral Immune Cells in Synaptic Repair 315\u003cbr\u003e10.6 Molecular Signals Mediating Immune-Synapse Communication 317\u003cbr\u003e10.7 Fractalkine and Other Key Signaling Pathways 319\u003cbr\u003e10.8 Neuroinflammation: Double-Edged Sword 320\u003cbr\u003e10.9 Synaptic Dysfunction in Neurodegenerative Diseases 322\u003cbr\u003e10.10 Therapeutic Strategies Targeting Immune Pathways 324\u003cbr\u003e10.11 Cell-Based Approaches to Promote Synaptic Healing 326\u003cbr\u003e10.12 Biomaterials and Immunomodulation 328\u003cbr\u003e10.13 Challenges and Risks in Manipulating Immune Responses 331\u003cbr\u003e10.14 Future Directions in Synaptic Repair Research 333\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Exploring Ion Channel-Linked Strategies in Immunotherapy for Neurological Disorders 341\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eHariprasad M.G., Sourav Guha and Moqbel Ali Moqbel Redhwan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Introduction 342\u003cbr\u003e11.2 Neurodegenerative Diseases and Their Pathophysiology 344\u003cbr\u003e11.3 Ion Channels and Their Types: Overview 349\u003cbr\u003e11.4 Types of Ion Channels in Neurons 355\u003cbr\u003e11.5 Ion Channels Present in Different Parts of Neurons 357\u003cbr\u003e11.6 Role of Ion Channels in Neuronal Excitability, Signaling, and Plasticity 359\u003cbr\u003e11.7 Immune Signaling in Neurodegeneration 361\u003cbr\u003e11.8 Immunotherapy 362\u003cbr\u003e11.9 Immunotherapy in Neurodegenerative Diseases 363\u003cbr\u003e11.10 Immunotherapy Approaches in Neurodegenerative Diseases 364\u003cbr\u003e11.11 Inhibiting Pathogenic Immune Signaling 366\u003cbr\u003e11.12 Intersection of Immunotherapy and Ion Channels 367\u003cbr\u003e11.13 Immunotherapeutic Agents Targeting Ion Channels in Neurodegenerative Disorders 368\u003cbr\u003e11.14 Challenges and Limitations of Immunotherapy in Neurodegenerative Disorders 370\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Strategies for Inflammation Control: Modulating Microglial Responses 385\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eFaizan Khalid, Ashwini Deshpande and D. S. N. B. K. Prasanth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Introduction 386\u003cbr\u003e12.2 Microglial Activation and Its Role in Inflammation 389\u003cbr\u003e12.3 Pathophysiological Implications of Microglial Dysregulation 391\u003cbr\u003e12.4 Molecular Targets for Modulating Microglial Responses 394\u003cbr\u003e12.5 Pharmacological Strategies 396\u003cbr\u003e12.6 Nonpharmacological Interventions 406\u003cbr\u003e12.7 Emerging Approaches and Future Directions 416\u003cbr\u003e12.8 Challenges and Limitations 419\u003cbr\u003e12.9 Conclusions 422\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Revolutionizing Neuroprotection: Innovative Lysosomal Targeting Strategies 433\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAhana Hazra, Rideb Chakraborty, Naureen Afrose, Pratibha Bhowmick and Mithun Bhowmick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 434\u003cbr\u003e13.2 Tackling of Neurodegeneration 435\u003cbr\u003e13.3 CNS-Targeting Treatments for Lysosomal Keeping Diseases: Current Advancements and Challenges 440\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Ensuring Safety: Immunotherapy and Adverse Effect Management in Cerebrospinal Fluid 461\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePankaj Malhotra, Neha Minocha, Prashant Tiwari, Sunil Kumar Kadiri and Sampriti Paul\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Introduction 462\u003cbr\u003e14.2 Role of Immunotherapy in Neurological Disorder 468\u003cbr\u003e14.3 Mechanisms of Adverse Effects in Immunotherapy 474\u003cbr\u003e14.4 Diagnostic Strategies for Adverse Effects 476\u003cbr\u003e14.5 Management of Immunotherapy in CSF Disorders 479\u003cbr\u003e14.6 Future Development 480\u003cbr\u003e14.7 Conclusion 484\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Phytosomes and Blood Barrier Integrity: Implications for Immunotherapy Sustainability 493\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eAkanksha and Sajeev Kumar B.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Introduction 494\u003cbr\u003e15.2 Considerations for Drug Delivery to the Brain 503\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Therapeutic Insights: Acetylcholinesterase Inhibitors and Immunotherapy for Alzheimer's Disease 521\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eRashmi Madhariya, Vikas Kumar, Prince Nikhil Rathore and Alpana Ram\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Introduction 522\u003cbr\u003e16.2 Acetylcholinesterase Inhibitors (AChEIs) 526\u003cbr\u003e16.3 Treatment for ADs Using Immunotherapy 535\u003cbr\u003e16.4 Comparative Insights: AChEIs vs. Immunotherapy 547\u003cbr\u003e16.5 Conclusion 549\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Hormonal Regulation in Immunotherapy for Brain Disorders: Insights and Innovations 559\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eMeghana G. S., Chinmayee U. Gowda, K. Trideva Sastri and Balamuralidhara V.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Introduction 560\u003cbr\u003e17.2 Hormonal Influence on Immune Function 563\u003cbr\u003e17.3 Hormones and Brain-Immune Crosstalk 567\u003cbr\u003e17.4 Innovations in Hormonal Regulation for Immunotherapy 571\u003cbr\u003e17.5 Synergistic Effects of Combining Hormone Therapy with Immunotherapies 574\u003cbr\u003e17.6 Tailored Approaches for Gender-Specific and Age-Specific Interventions 576\u003cbr\u003e17.7 Challenges and Limitations 576\u003cbr\u003e17.8 Future Directions 578\u003cbr\u003e17.9 Conclusion 581\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Challenges and Opportunities of Tuberoinfundibular Axis in Brain Disorder Immunotherapy 589\u003c\/b\u003e\u003cbr\u003e\u003ci\u003ePranita Jirvankar, Deepak Khobragade, Surendra Agrawal, Mrunali Potbhare, Prashant Tiwari and Sunil Kumar Kadiri\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Introduction 590\u003cbr\u003e18.2 Hypophyseal Portal System: A Key Neurovascular Link 591\u003cbr\u003e18.3 Functional Significance of the Hypophyseal Portal System 595\u003cbr\u003e18.4 Clinical Implications of the Hypophyseal Portal System 596\u003cbr\u003e18.5 Clinical Relevance of TIA Dysfunction 597\u003cbr\u003e18.6 Role of the Tuberoinfundibular Axis (TIA) in Neuroendocrine Regulation 600\u003cbr\u003e18.7 Significance of the Tuberoinfundibular Axis (TIA) in Brain Disorder Immunotherapy 603\u003cbr\u003e18.8 Neuroanatomy and Function of the Tuberoinfundibular Axis 606\u003cbr\u003e18.9 Role of the Tuberoinfundibular Axis (TIA) in Hormonal Homeostasis 612\u003cbr\u003e18.10 Dopamine and Prolactin Regulation in the Tuberoinfundibular Axis 616\u003cbr\u003e18.11 Immune System Interactions with the Tuberoinfundibular Axis 617\u003cbr\u003e18.12 Role of Cytokines in Modulating Dopaminergic Activity 621\u003cbr\u003e18.13 Blood-Brain Barrier and Immune Cell Infiltration in the Tuberoinfundibular Axis 623\u003cbr\u003e18.14 Opportunities for Therapeutic Interventions 624\u003cbr\u003e18.15 Potential of Gene Therapy and Cell-Based Approaches 625\u003cbr\u003e18.16 Case Studies and Current Research Trends 626\u003cbr\u003e18.17 Future Perspectives and Research Directions 626\u003cbr\u003e18.18 Conclusion 627\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Immunotherapy in Alzheimer's Disease: Regulatory Considerations and Current Clinical Trial Landscape 635\u003c\/b\u003e\u003cbr\u003e\u003ci\u003eMangal Jyoti Das and Pratap Kumar Sahu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Introduction 636\u003cbr\u003e19.2 Immunotherapy in Alzheimer's Disease 637\u003cbr\u003e19.3 Regulatory Considerations 640\u003cbr\u003e19.4 Current Clinical Trial Landscape 644\u003cbr\u003e19.5 Challenges 656\u003cbr\u003e19.6 Conclusion 658\u003cbr\u003e19.7 Future Directions 659\u003c\/p\u003e \u003cp\u003eReferences 661\u003cbr\u003eIndex 669\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Clinical \u0026amp; internal medicine [\u003ca title=\"See our other books on Clinical \u0026amp; internal medicine\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Clinical%20\u0026amp;%20internal%20medicine%20%5BMJ%5D%22\"\u003eMJ\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley-Scrivener","offers":[{"title":"Brand New","offer_id":52433818222872,"sku":"9781394336210","price":246.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9781394336210.jpg?v=1784853941","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/immunotherapy-in-alzheimers-disease-hardback-9781394336210","provider":"Freshly Printed Books","version":"1.0","type":"link"}